Patents by Inventor Claire Louise Langrish

Claire Louise Langrish has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST HUMAN IL17 AND USES THEREOF
    Publication number: 20130195844
    Abstract: An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.
    Type: Application
    Filed: July 19, 2011
    Publication date: August 1, 2013
    Inventors: Johannes Auer, Nikolaos Dimoudis, Guy Georges, Petra Hanke, Hendrik Knoetgen, Ekkehard Moessner, Claire Louise Langrish
  • Antibodies against human IL17 and uses thereof
    Patent number: 8003099
    Abstract: An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: August 23, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Johannes Auer, Nikolaos Dimoudis, Guy Georges, Petra Hanke, Hendrik Knoetgen, Ekkehard Moessner, Claire Louise Langrish
  • Antibodies against human IL17 and uses thereof
    Publication number: 20100080812
    Abstract: An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.
    Type: Application
    Filed: September 29, 2009
    Publication date: April 1, 2010
    Inventors: Johannes Auer, Nikolaos Dimoudis, Guy Georges, Petra Hanke, Hendrik Knoetgen, Ekkehard Moessner, Claire Louise Langrish